Clinical Trials
2 trialsNCT06058377 2026-06-05
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06954480 2026-05-22
DIAMOND
Queen Mary University of London
Phase 2 Recruiting